CALGARY, Nov. 11, 2011 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC,
NASDAQ: ONCY) ("Oncolytics") today announced that Dr. Brad Thompson,
President and CEO of Oncolytics, will host a conference call and
webcast on Monday, November 14th, 2011 at 6:30 a.m. MT (8:30 a.m. ET) to discuss in more depth clinical
data being presented at the AACR-NCI-EORTC Molecular Targets and Cancer
Therapeutics Conference being held in San Francisco, CA from November
12th to 16th, 2011.
To access the conference call by telephone, dial 1-647-427-7450 or
1-888-231-8191. A live audio webcast will also be available at the
following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3743300 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 10 minutes prior to the webcast to ensure
adequate time for any software download that may be needed. A replay of
the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through November 21st, 2011. To access the telephone replay, dial 1-416-849-0833 or
1-855-859-2056 and enter reservation number 27729561 followed by the
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including the implication of the
materials to be presented at the AACR-NCI-EORTC conference with respect
to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a
cancer therapeutic; the Company's expectations as to the success of its
research and development programs in 2011 and beyond, the Company's
planned operations, the value of the additional patents and
intellectual property; the Company's expectations related to the
applications of the patented technology; the Company's expectations as
to adequacy of its existing capital resources; the design, timing,
success of planned clinical trial programs; and other statements
related to anticipated developments in the Company's business and
technologies involve known and unknown risks and uncertainties, which
could cause the Company's actual results to differ materially from
those in the forward-looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN as a
cancer treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and
general changes to the economic environment. Investors should consult
the Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors
are cautioned against placing undue reliance on forward-looking
statements. The Company does not undertake to update these
forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information:
| The Equicom Group |
300 5th Ave. SW, 10th Floor
Calgary, Alberta T2P 3C4
| The Investor Relations Group |
11 Stone St, 3rd Floor
New York, NY10004